The American Journal of Managed Care

Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671

In Perioperative Immunotherapy Advances: Insights from CheckMate-77T and KEYNOTE-671, our panel delves into the following ...
The American Journal of Managed Care

Evolving Role of PD-L1 and Neoadjuvant Immunotherapy in Resectable NSCLC

Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the pivotal CheckMate 816 trial, which established neoadjuvant nivolumab plus ...
CURE

FDA Clears PD-L1 Test to Guide Keytruda Use in Ovarian Cancer

FDA approved a PD-L1 companion test to identify patients with ovarian, fallopian tube or primary peritoneal cancer who may receive first-line Keytruda. The U.S. Food and Drug Administration (FDA) has ...
ascopubs.org

Efficacy and safety of enlonstobart (SG001), a PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer: A multicenter, single-arm, open-label, phase ...

Value of ctDNA-based molecular residual disease (MRD) in evaluating the adjuvant therapy effect in ovarian cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract ...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic ...

PD-1/PD-L1 Checkpoint Inhibitors Market Research and Global Forecast Report 2026-2032

The PD-1/PD-L1 market offers opportunities in therapy combinations, real-world data use, and digital patient support. With growth in specialty distribution channels, regional strategies, and ...